Daily Oral Memantine Attenuated the Severity of Borderline Personality Disorder Symptoms: A Double-Blind Placebo-Controlled, Randomized Clinical Trial

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MOHAMMAD SADEGHI HOMA; SOLEIMANNEJAD MARYAM; Ramazi Samira; Shalbafan Mohammadreza; Eftekhar Ardebili Mehrdad; VAHABZADEH GELAREH; AHMADIRAD NOOSHIN; KARIMZADEH FARIBA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Psychiatry and Behavioral Sciences Year:2023 | Volume:17 | Issue:2 Page(s): 0-0

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Daily Oral Memantine Attenuated the Severity of Borderline Personality Disorder Symptoms: A Double-Blind Placebo-Controlled, Randomized Clinical Trial

Author(s)

Keywords

Borderline Personality Disorder

Memantine

Mood Disorder

N-Methyl-D-aspartate

Wisconsin

Abstract

Background: Borderline Personality Disorder (BPD) has been considered a psychiatric disorder, the eﬀ, ective pharmacological treatments for which have not been well established. Objectives: This study aimed to assess the eﬃ, cacy of Memantine (10 mg/day) in reducing BPD severity and cognitive impairment. Methods: The BPD patients diagnosed by psychologists were included and divided into the placebo (n = 19) and Memantine (n = 20) groups. Included participants were randomized, double-blinded, and stabilized on the medication and psychotherapy for at least four weeks. The patients in the Memantine group received oral Memantine (10 mg/day) for four weeks. The severity of BPD was assessed by a self-reported questionnaire named Borderline Evaluation of Severity Over Time (BEST). Moreover, the Wisconsin test was carried out to assess executive function. Results: The mean score of the BEST test signiﬁ, cantly decreased in week eight post-treatment in the Memantine group. In addition, a signiﬁ, cant decrease in this score was indicated in the Memantine group compared to the placebo group in week eight. The mean total score of the BEST test was not signiﬁ, cantly diﬀ, erent before and after the placebo administration. There was no signiﬁ, cant diﬀ, erence in the Wisconsin subscales, including the number of wrong answers and categories achieved after Memantine or placebo administration. Perseverative errors rose after the administration of Memantine. Adverse side eﬀ, ects did not occur in any of the participants. Conclusions: Our ﬁ, ndings suggested the potential therapeutic eﬀ, ects of Memantine for BPD. Furthermore, we found that a low dose of meantime might be preferable to prevent the side effects.

Cites

No record.

References

No record.

Cite

APA: Copy

SOLEIMANNEJAD, MARYAM, Ramazi, Samira, Shalbafan, Mohammadreza, Eftekhar Ardebili, Mehrdad, VAHABZADEH, GELAREH, AHMADIRAD, NOOSHIN, & KARIMZADEH, FARIBA. (2023). Daily Oral Memantine Attenuated the Severity of Borderline Personality Disorder Symptoms: A Double-Blind Placebo-Controlled, Randomized Clinical Trial. IRANIAN JOURNAL OF PSYCHIATRY AND BEHAVIORAL SCIENCES (IJPBS), 17(2), 0-0. SID. https://sid.ir/paper/1113145/en

Vancouver: Copy

SOLEIMANNEJAD MARYAM, Ramazi Samira, Shalbafan Mohammadreza, Eftekhar Ardebili Mehrdad, VAHABZADEH GELAREH, AHMADIRAD NOOSHIN, KARIMZADEH FARIBA. Daily Oral Memantine Attenuated the Severity of Borderline Personality Disorder Symptoms: A Double-Blind Placebo-Controlled, Randomized Clinical Trial. IRANIAN JOURNAL OF PSYCHIATRY AND BEHAVIORAL SCIENCES (IJPBS)[Internet]. 2023;17(2):0-0. Available from: https://sid.ir/paper/1113145/en

IEEE: Copy

MARYAM SOLEIMANNEJAD, Samira Ramazi, Mohammadreza Shalbafan, Mehrdad Eftekhar Ardebili, GELAREH VAHABZADEH, NOOSHIN AHMADIRAD, and FARIBA KARIMZADEH, “Daily Oral Memantine Attenuated the Severity of Borderline Personality Disorder Symptoms: A Double-Blind Placebo-Controlled, Randomized Clinical Trial,” IRANIAN JOURNAL OF PSYCHIATRY AND BEHAVIORAL SCIENCES (IJPBS), vol. 17, no. 2, pp. 0–0, 2023, [Online]. Available: https://sid.ir/paper/1113145/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops